profit from every $100 of sales.
$0$100
Perrigo
$16.24+0.37% today
+16.2% in 1 year
1-year low $9.251-year high $16.95
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Perrigo sold, what it kept, and what it did with the cash.
Sales went from $4.45 billion in 2022 to $4.25 billion in 2025, with -$1.43 billion of profit last year.
SalesProfit
Perrigo handed back more cash to shareholders than it generated last year.
$159M
Free cash flow 2025$145M
Bought back its own shares–
Paid as dividends$159M
Cash vs. debt$532M vs. $3.6B
Perrigo vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Perrigo | No profit yet | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 102.5× · Very expensive | ||
 Galderma Group | 86.9× · Very expensive | ||
 Teva Pharmaceutical Industries | 36.8× · Expensive |
AI analysis
An AI analyst reads Perrigo's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 4,452 | 4,656 | 4,373 | 4,253 | |
| 1,455 | 1,680 | 1,543 | 1,495 | |
| 121 | 284 | 312 | 313 | |
| 356 | 525 | 433 | -798 | |
| -141 | -13 | -172 | -1,425 | |
| -1.04 | -0.09 | -1.25 | -10.29 | |
| 32.7% | 36.1% | 35.3% | 35.1% | |
| 2.7% | 6.1% | 7.1% | 7.4% | |
| -3.2% | -0.3% | -3.9% | -33.5% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 11,017 | 10,809 | 9,648 | 8,535 |
| Cash | 601 | 751 | 559 | 532 |
| Total debt | 4,107 | 4,073 | 3,618 | 3,640 |
| Total liabilities | 6,175 | 6,041 | 5,328 | 5,600 |
| 4,842 | 4,768 | 4,319 | 2,936 | |
| 135 | 135 | 137 | 139 | |
| 0.1% | 1.5% | 1.1% | -13.6% | |
| -2.9% | -0.3% | -4.0% | -48.6% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 307 | 406 | 363 | 239 | |
| 96 | 102 | 118 | 93 | |
| 211 | 304 | 245 | 145 | |
| Dividends paid | 142 | 150 | 153 | 159 |
| 0 | – | – | – | |
| 55 | 69 | 64 | 55 |
Valuation
- –
- 7.7×
- –
- 0.6×
- 0.5×
- 15.5×
- –
- 6.4%
- -63.2%
- 10.7%
Profitability
- 35.1%
- 7.4%
- -33.5%
- -20.0%
- 3.4%
- -5.1%
- -50.7%
- -22.8%
- 3.4%
- 2.2%
Growth
- −1.5%
- –
- −40.7%
- +5.2%
- +0.9%
Financial health
- –
- 1.52
- 47.7%
- 1.4×
- 2.72
- 1.59
- 0.52
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 41%of 952
Bottom 43%of 884
Bottom 15%of 886
Top 16%of 987
What analysts expect
- Average price target
- $20.00
- Range
- $20.00 – $20.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 6, 2026 | 0.43 | 0.39 | +10.3% |
| Feb 26, 2026 | 0.77 | 0.80 | −3.8% |
| Nov 5, 2025 | 0.80 | 0.75 | +6.7% |
| Aug 6, 2025 | 0.57 | 0.59 | −3.4% |
| May 7, 2025 | 0.60 | 0.56 | +7.1% |
| Feb 27, 2025 | 0.93 | 0.92 | +1.1% |
| Nov 6, 2024 | 0.81 | 0.82 | −1.2% |
| Aug 2, 2024 | 0.53 | 0.48 | +10.4% |
10.7%of the share price, paid each year
On $1,000 invested$107a year at today's yield, before tax
+5.2%2020 to 2025
Raised10 yearsin a row, in our data
Paid per share, each year
$0.50 in 2015 → $1.16 in 2025
How safe it looks
-8.7% of its profit
Room to growStretchedMore than it earns: 109.8%
News
Perrigo (PRGO) Rebounds as Bad News Turns Less BadYahoo Finance · Nov 3, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
26No pass
Benjamin Graham
60Pass
Philip Fisher
26No pass
Peter Lynch
14No pass
Joel Greenblatt
0No pass
Charlie Munger
20No pass
Terry Smith
20No pass
Questions about Perrigo
Is Perrigo a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Perrigo AI analysis
What does Perrigo do?
Perrigo Company plc provides over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to prevent or treat conditions that can be self-managed. It is in Drug Manufacturers - Specialty & Generic.
Does Perrigo pay a dividend?
Yes. At today's price the dividend is 10.7% a year. In 2025 it paid out $159 million in dividends.
Is Perrigo stock halal?
No. Perrigo does not pass our halal screen: its debt is 162% of its market value, at or above the 33% limit. How we check
How has Perrigo stock done over the past year?
Up 16.2% over the past twelve months, to $16.24. It traded between $9.25 and $16.95 and is 4.2% below its high.
Who are Perrigo's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Perrigo's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.